Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism.

Kidney Int Rep · 2023 · PMC10658267 · PMID 38025238

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

14 , 15 In the EVOLVE trial, cinacalcet led to nominally significant decreases in the risk of death or first myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event. 14 Furthermore, in the ADVANCE trial, cinacalcet combined with vitamin D decreased vascular and cardiac valve calcification scores. 15 Cinacalcet can re

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.